Biodegradable Core-Shell Copolymer-Phospholipid Nanoparticles for Combination Chemotherapy: An In Vitro Study

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Combination chemotherapy requires effective delivery systems for synergistic drug action.
• Developing hybrid nanoparticles with distinct drug loading capabilities is crucial for enhanced therapeutic outcomes.

Purpose of the Study:

• To engineer core-shell lipid/particle assemblies for co-delivery of hydrophobic dihydroartemisinin and hydrophilic doxorubicin.
• To evaluate the physicochemical properties and therapeutic efficacy of these novel hybrid nanoparticles.

Main Methods:

• Fabrication of poly(lactic-co-glycolic acid) nanoparticle cores coated with a 1,2-dipalmitoyl-sn-glycero-3-phosphocholine shell.
• Co-loading of dihydroartemisinin and doxorubicin into the core-shell structures.
• Characterization of physicochemical properties, cell viability assays, and cellular uptake studies.

Main Results:

• The developed core-shell lipid/particle assemblies exhibited desirable physicochemical properties for dual drug delivery.
• These hybrid nanoparticles significantly enhanced doxorubicin accumulation within cell nuclei.
• Improved cellular uptake led to increased cytotoxicity and synergistic therapeutic effects of dihydroartemisinin and doxorubicin.

Conclusions:

• Biodegradable lipid/polymer hybrid particles represent a promising platform for advanced combination chemotherapy.
• The core-shell architecture facilitates effective co-delivery and enhances the efficacy of chemotherapeutic agents.
• This delivery system holds potential for improving treatment efficiency in cancer therapy.